ARTICLE | Product Development
COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 31, 2020 10:44 PM UTC
Updated on Apr 1, 2020 at 4:57 PM UTC
FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients.
The test from Qiagen N.V. (Xetra:QIA; NYSE:QGEN) can produce results in about one hour. The QIAstat-Dx Respiratory SARS-CoV-2 Panel is a multiplexed nucleic acid-based diagnostic that differentiates COVID-19 from 20 other serious respiratory infections by detecting two SARS-CoV-2 genes...